Cargando…

Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion

Introduction Platelet additive solutions (PASs) are nutrient media commonly used to replace and reduce the need for storage plasma. They are an alternative medium to maintain high-quality platelets lasting longer on the shelf for about seven days. Platelets with high titer of ABO antibody can pose a...

Descripción completa

Detalles Bibliográficos
Autores principales: Adzahar, Sumaiyah, Hassan, Mohd Nazri, Zulkafli, Zefarina, Mohd Noor, Noor Haslina, Ramli, Marini, Mohamed Yusoff, Shafini, Lam, Sien Tzi, Deshpande, Rajesh, Abdullah, Wan Zaidah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517286/
https://www.ncbi.nlm.nih.gov/pubmed/37746385
http://dx.doi.org/10.7759/cureus.44012
_version_ 1785109291146936320
author Adzahar, Sumaiyah
Hassan, Mohd Nazri
Zulkafli, Zefarina
Mohd Noor, Noor Haslina
Ramli, Marini
Mohamed Yusoff, Shafini
Lam, Sien Tzi
Deshpande, Rajesh
Abdullah, Wan Zaidah
author_facet Adzahar, Sumaiyah
Hassan, Mohd Nazri
Zulkafli, Zefarina
Mohd Noor, Noor Haslina
Ramli, Marini
Mohamed Yusoff, Shafini
Lam, Sien Tzi
Deshpande, Rajesh
Abdullah, Wan Zaidah
author_sort Adzahar, Sumaiyah
collection PubMed
description Introduction Platelet additive solutions (PASs) are nutrient media commonly used to replace and reduce the need for storage plasma. They are an alternative medium to maintain high-quality platelets lasting longer on the shelf for about seven days. Platelets with high titer of ABO antibody can pose a hemolytic transfusion reaction (HTR) risk if units are given across the ABO barrier. The risk of complication is greater when group O platelet is released to non-group O patients. The PAS has been known as a safe medium, where the titer of ABO antibodies is expected to be diluted. In this study, we compared the anti-A and anti-B antibody titers of apheresis platelets in PAS and non-PAS (plasma) as the suspending media. Methods A total of 20 apheresis platelet donors were selected, with seven from blood group A, eight from blood group B, and five from blood group O. The platelets were collected using an Amicus cell separator. They were suspended in PAS and plasma before being stored at a temperature range of 22-24(º )C. Anti-A (blood group B and O) and Anti-B (blood group A and O) antibody titers were measured and compared between the two suspending media. Wilcoxon signed-rank test is used for statistical analysis, and a p-value <0.05 is considered significant. Results The median titer of the anti-A antibody of apheresis platelets showed a significant difference between suspended in PAS (2.50) and plasma (4.00), p=0.002. Similar findings were also seen with the median titer of the anti-B antibody of apheresis platelet, in which it showed a significant difference between suspended in PAS (2.00) and plasma (4.00), p=0.004. It was observed that there was a significant reduction in both anti-A and anti-B antibody titers in the PAS as compared to the plasma group. Conclusion The decrease in ABO antibody titer in apheresis platelets stored with PAS can be beneficial for patients. This reduces the risk of HTRs if ABO-incompatible platelet units need to be issued. Thus, using PAS as a storage medium significantly improves platelet inventory management without compromising patient safety.
format Online
Article
Text
id pubmed-10517286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105172862023-09-24 Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion Adzahar, Sumaiyah Hassan, Mohd Nazri Zulkafli, Zefarina Mohd Noor, Noor Haslina Ramli, Marini Mohamed Yusoff, Shafini Lam, Sien Tzi Deshpande, Rajesh Abdullah, Wan Zaidah Cureus Hematology Introduction Platelet additive solutions (PASs) are nutrient media commonly used to replace and reduce the need for storage plasma. They are an alternative medium to maintain high-quality platelets lasting longer on the shelf for about seven days. Platelets with high titer of ABO antibody can pose a hemolytic transfusion reaction (HTR) risk if units are given across the ABO barrier. The risk of complication is greater when group O platelet is released to non-group O patients. The PAS has been known as a safe medium, where the titer of ABO antibodies is expected to be diluted. In this study, we compared the anti-A and anti-B antibody titers of apheresis platelets in PAS and non-PAS (plasma) as the suspending media. Methods A total of 20 apheresis platelet donors were selected, with seven from blood group A, eight from blood group B, and five from blood group O. The platelets were collected using an Amicus cell separator. They were suspended in PAS and plasma before being stored at a temperature range of 22-24(º )C. Anti-A (blood group B and O) and Anti-B (blood group A and O) antibody titers were measured and compared between the two suspending media. Wilcoxon signed-rank test is used for statistical analysis, and a p-value <0.05 is considered significant. Results The median titer of the anti-A antibody of apheresis platelets showed a significant difference between suspended in PAS (2.50) and plasma (4.00), p=0.002. Similar findings were also seen with the median titer of the anti-B antibody of apheresis platelet, in which it showed a significant difference between suspended in PAS (2.00) and plasma (4.00), p=0.004. It was observed that there was a significant reduction in both anti-A and anti-B antibody titers in the PAS as compared to the plasma group. Conclusion The decrease in ABO antibody titer in apheresis platelets stored with PAS can be beneficial for patients. This reduces the risk of HTRs if ABO-incompatible platelet units need to be issued. Thus, using PAS as a storage medium significantly improves platelet inventory management without compromising patient safety. Cureus 2023-08-23 /pmc/articles/PMC10517286/ /pubmed/37746385 http://dx.doi.org/10.7759/cureus.44012 Text en Copyright © 2023, Adzahar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Hematology
Adzahar, Sumaiyah
Hassan, Mohd Nazri
Zulkafli, Zefarina
Mohd Noor, Noor Haslina
Ramli, Marini
Mohamed Yusoff, Shafini
Lam, Sien Tzi
Deshpande, Rajesh
Abdullah, Wan Zaidah
Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title_full Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title_fullStr Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title_full_unstemmed Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title_short Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion
title_sort platelet additive solutions as an alternative storage medium of apheresis platelets to reduce abo antibody titer for abo-incompatibility platelet transfusion
topic Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517286/
https://www.ncbi.nlm.nih.gov/pubmed/37746385
http://dx.doi.org/10.7759/cureus.44012
work_keys_str_mv AT adzaharsumaiyah plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT hassanmohdnazri plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT zulkaflizefarina plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT mohdnoornoorhaslina plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT ramlimarini plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT mohamedyusoffshafini plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT lamsientzi plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT deshpanderajesh plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion
AT abdullahwanzaidah plateletadditivesolutionsasanalternativestoragemediumofapheresisplateletstoreduceaboantibodytiterforaboincompatibilityplatelettransfusion